STAA
STAAR Surgical Company24.80
+1.24+5.26%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Reaffirms stability, tempers hypergrowth.
Q&A reinforced prepared optimism on China inventory normalization—now stable below contractual levels with weekly tracking and a new APAC leader—but explicitly ruled out 2023-style 20-25% hypergrowth for 2026, targeting instead 'nice growth.' China remains the clear priority over U.S. double-digit gains on a lean budget. No VBP threats or post-merger turnover emerged; EVO+ draws premium pricing excitement sans quantification. Seasonality holds for strong Q2/Q3. Management dodged precise forecasts. China reigns supreme. Cautious tone signals watch execution on demand rebound and innovation milestones.
Key Stats
Market Cap
1.22BP/E (TTM)
-Basic EPS (TTM)
-1.96Dividend Yield
0%Recent Filings
8-K
Q4 sales up 18%, FY down 24%
STAAR Surgical reported Q4 net sales of $57.8M, up 18.1% year/year, driven by China recovery, while full-year sales fell 23.7% to $239.4M amid inventory normalization. Gross margin jumped to 75.7% from 64.7%, but Q4 net loss narrowed to $(18.3)M versus $(34.2)M prior. Interim co-CEOs took helm February 2; merger costs hit $11.2M. China poised for 2026 growth.
10-K
FY2025 results
STAAR Surgical's FY2025 net sales fell 23.7% y/y to $239.4M, driven by a 32% APAC drop as China sales halved to $77.8M amid sluggish demand and normalized distributor inventory, yet U.S. grew 14% and EMEA 3% with Q4 unit momentum in non-China markets. Gross margins held steady at 76.2% despite dual-site manufacturing pressures, but operating loss widened to 38.3% of sales from $17.1M merger costs and $28.6M restructuring charges. Cash burned $34M in operations yet ended at $187.5M with $23.5M buyback capacity remaining. China macro weakness risks quarterly momentum.
8-K
CLO Sisitsky exits abruptly
STAAR Surgical's Chief Legal Officer Nathaniel Sisitsky exited February 4, 2026, treated as without cause, triggering 12 months base salary, benefits, full 2025 bonus, $75,000 retention installment, and accelerated March RSUs. Other equity forfeited. He'll consult through March 13 at $8,000 weekly plus $10,000 completion fee. Smooth legal transition ahead.
8-K
Interim co-CEOs appointed
STAAR Surgical appointed Warren Foust and Deborah Andrews as Interim Co-CEOs effective February 1, 2026, following Stephen Farrell's exit on January 31 amid a Broadwood Partners cooperation agreement. Foust, ex-J&J Surgical Vision head, and Andrews, veteran CFO, add the role atop their duties while a search committee hunts a permanent leader. Each gets $375,000 RSUs vesting August 1. Transition underway.
8-K
New Board Chair, CEO search
STAAR Surgical elected Neal C. Bradsher, founder of largest shareholder Broadwood Partners, as Board Chair effective January 15, 2026, while reshuffling its standing committees with independent directors and forming a Search Committee for CEO successor and an Insight and Engagement Committee. This regains NASDAQ audit committee independence compliance. Leadership hunt underway.
IPO
Website
Employees
Sector
Industry
ALC
Alcon Inc.
79.02-0.17
BLCO
Bausch + Lomb Corporation
16.98-0.11
COO
The Cooper Companies, Inc.
81.04-0.49
ISRG
Intuitive Surgical, Inc.
554.58-4.94
LNSR
LENSAR, Inc.
12.06+0.54
POCI
Precision Optics Corporation, I
4.20-0.07
RXST
RxSight, Inc.
12.76+0.24
SGHT
Sight Sciences, Inc.
8.39+0.08
SSII
SS Innovations International In
5.50+0.41
STSS
Sharps Technology Inc.
2.22+0.00